Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OmniAb, Inc. - Common Stock (NQ:OABI)

2.055 +0.185 (+9.89%)
Streaming Delayed Price Updated: 2:44 PM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about OmniAb, Inc. - Common Stock

< Previous 1 2 Next >
OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit
From OmniAb, Inc.
Via Business Wire
OmniAb Reports First Quarter 2025 Financial Results and Business Highlights
From OmniAb, Inc.
Via Business Wire
OmniAb Introduces the xPloration® Partner Access Program
From OmniAb, Inc.
Via Business Wire
OmniAb to Participate in Five Upcoming Investor Conferences
From OmniAb, Inc.
Via Business Wire
OmniAb Announces Two New Appointments to its Board of Directors
From OmniAb, Inc.
Via Business Wire
OmniAb to Report First Quarter 2025 Financial Results on May 8
From OmniAb, Inc.
Via Business Wire
OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
From OmniAb, Inc.
Via Business Wire
OmniAb to Report Fourth Quarter 2024 Financial Results on March 18
From OmniAb, Inc.
Via Business Wire
OmniAb to Participate in Two Investor Conferences in March
From OmniAb, Inc.
Via Business Wire
OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
From OmniAb, Inc.
Via Business Wire
OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights
From OmniAb, Inc.
Via Business Wire
OmniAb to Participate in Two Investor Conferences in November
From OmniAb, Inc.
Via Business Wire
OmniAb to Report Third Quarter 2024 Financial Results on November 12
From OmniAb, Inc.
Via Business Wire
OmniAb to Participate in Two Investor Conferences in September
From OmniAb, Inc.
Via Business Wire
OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights
From OmniAb, Inc.
Via Business Wire
OmniAb to Report Second Quarter 2024 Financial Results on August 8
From OmniAb, Inc.
Via Business Wire
OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology
From OmniAb, Inc.
Via Business Wire
OmniAb to Participate in the Jefferies Global Healthcare Conference
From OmniAb, Inc.
Via Business Wire
OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit
From OmniAb, Inc.
Via Business Wire
OmniAb Reports First Quarter 2024 Financial Results and Business Highlights
From OmniAb, Inc.
Via Business Wire
OmniAb to Participate in Five Investor Conferences in May
From OmniAb, Inc.
Via Business Wire
OmniAb to Report First Quarter 2024 Financial Results on May 9
From OmniAb, Inc.
Via Business Wire
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From OmniAb, Inc.
Via Business Wire
OmniAb to Report Fourth Quarter 2023 Financial Results on March 20
From OmniAb, Inc.
Via Business Wire
OmniAb to Participate in Two Investor Conferences in March
From OmniAb, Inc.
Via Business Wire
OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference
From OmniAb, Inc.
Via Business Wire
OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today’s Research & Technology Virtual Event
From OmniAb, Inc.
Via Business Wire
OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights
From OmniAb, Inc.
Via Business Wire
OmniAb to Participate in Two Investor Conferences in November
From OmniAb, Inc.
Via Business Wire
OmniAb Appoints Steve Love to its Board of Directors
From OmniAb, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.